Moderna Plunges After Melanoma Data Leak — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Moderna shares plunged after cancer-vaccine data were shared on social media, with leaked melanoma figures threatening the company’s record August rally.
- Moderna and Merck said their mRNA cancer vaccine cut both death and recurrence by 42%.
Why it matters: Moderna shareholders faced an immediate plunge after the record August rally once melanoma-vaccine data were shared on social media. The key tension is between that market move and Moderna and Merck’s stated 42% cut in death and recurrence, making the disclosure route and timing central to the episode.
Ask SkimNews
